192185-68-5

Basic information

• Product Name: 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chloroph enyl)-1-methyl-quinolin-2-one
• Synonyms: 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chloroph enyl)-1-methyl-quinolin-2-one
• CAS NO: 192185-68-5
• Molecular Formula: C₂₇H₂₂Cl₂N₄O
• Molecular Weight: 0
• Mol File: 192185-68-5.mol

Chemical Properties

• Boiling Point: 681.7°Cat760mmHg
• Flash Point: 366.1°C
• Appearance: /
• Density: 1.33g/cm³
• Vapor Pressure: 1.94E-18mmHg at 25°C
• Refractive Index: 1.671
• CAS DataBase Reference: 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chloroph enyl)-1-methyl-quinolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chloroph enyl)-1-methyl-quinolin-2-one(192185-68-5)
• EPA Substance Registry System: 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chloroph enyl)-1-methyl-quinolin-2-one(192185-68-5)

Safety Data

• Hazardous Substances Data: 192185-68-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3

Upstream product

• 192185-51-6 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 
• 192187-31-8 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-2(1H)-quinolinone 
• 406161-72-6 N-[4-bromo-2-(3-chlorobenzoyl)phenyl]acetamide 
• 288391-74-2 6-bromo-4-(3-chloro-phenyl)-1H-quinolin-2-one 
• 280143-23-9 6-bromo-2-chloro-4-(3-chlorophenyl)quinoline 
• 190898-86-3 6-bromo-4-(3-chloro-phenyl)-2-methoxy-quinoline 
• 192187-30-7 4-(3-chlorophenyl)-3,4-dihydro-2(1H)-quinolinone 
• 288391-73-1 5-Bromo-3-(3-chloro-phenyl)-benzo[c]isoxazole 
• 405548-67-6 N-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide 
• 192187-32-9 R₁₀₁₇₆₃ 
• 192187-33-0 R₁₀₄₂₀₉ 
• 406162-21-8 (4-chlorophenyl)-[4-(3-chlorophenyl)-2-methoxyquinolin-6-yl]methanone 
• 190898-77-2 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2,1-benzisoxazole 
• 190898-78-3 [2-amino-5-(4-chlorobenzoyl)phenyl](3-chlorophenyl)-methanone 

Downstream Products

• 192185-72-1 tipifarnib 

Relevant articles and documents

SYNTHESIS OF TIPIFARNIB

Provided herein are methods of preparing a desired enantiomer 6-[amino(4- chlorophenyl) (1 -methyl- 1H-imidazol-5-yl) methy1]-4-(3-chlorophenyl)-1 -methyl-2(1H)- quinolinone, otherwise known as tipifarnib.

Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA

The discovery that post-translational farnesylation of Ras oncoprotein was an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRA) is currently undergoing clinical evaluation and recent studies have confirmed its antitumor potential and low toxicity. We wish to describe here the chemical synthesis routes that our group have developed to access ZARNESTRA. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties

The present invention is concerned with the finding that farnesyl protein transferase inhibitors have radiosensitizing properties which makes them useful for preparing a pharmaceutical composition for administration before, during or after irradiation of a tumor for treating cancer in vivo.

Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives

PCT No. PCT/EP96/04515 Sec. 371 Date May 26, 1998 Sec. 102(e) Date May 26, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/21701 PCT Pub. Date Jun. 19, 1997This invention comprises the novel compounds of formula (I) wherein the dotted line represents an op